Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Implication of Inherited Genetic Variants Associated with Follicular Lymphoma Susceptibility in the Prognosis of Patients Treated By Immunochemotherapy in PRIMA Study

Herve Ghesquieres, MD PhD, Youenn Drouet, PhD, Sarah Huet, PharmD PhD, Guillaume Cartron, Marie-Helene Delfau, MD PhD, Fritz Offner, MD, Pauline Brice, Luc Xerri, MD PhD, Reda Bouabdallah, Gilles A. Salles, MD PhD

Blood (2019) 134 (Supplement_1): 2780.

https://doi.org/10.1182/blood-2019-130357

Published: 2019

Journal Articles

Individualized Prediction of Follicular Lymphoma Risk Using a Combination of Blood t(14;18) Frequency Years before Diagnosis and a Polygenic Risk Score (PRS) of 9 SNPs Associated with Follicular Lymphoma Susceptibility

Herve Ghesquieres, MD PhD, Youenn Drouet, PhD, Manon Zala, Paolo Vineis, PhD, Gilles A. Salles, MD PhD, Bertrand Nadel, PhD, Sandrine Roulland, PharmD, PhD

Blood (2019) 134 (Supplement_1): 2775.

https://doi.org/10.1182/blood-2019-130618

Published: 2019

Journal Articles

Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results

Jacques Vargaftig, MD PhD, Hassan Farhat, MD, Lionel Ades, MD PhD, Adrien Briaux, Camille Benoist, Isabelle Turbiez, Norbert Vey, MD PhD, Sylvie Glaisner, MD, Céline Callens, PharmD, PhD

Blood (2018) 132 (Supplement 1): 5233.

https://doi.org/10.1182/blood-2018-99-117485

Published: 2018

Journal Articles

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 445.

https://doi.org/10.1182/blood-2018-99-110861

Published: 2018

Journal Articles

Autonomous Ca 2+ Oscillations Reflect Oncogenic BCR-Signaling in Multiple B-Cell Malignancies and Are Essential for Survival and Proliferation

Kohei Kume, PhD, Liting Chen, PhD, Jae-Woong Lee, PhD, Markus Muschen, MD

Blood (2018) 132 (Supplement 1): 1373.

https://doi.org/10.1182/blood-2018-99-117315

Published: 2018

Journal Articles

Vemurafenib in Advanced Patients with Hairy Cell Leukemia (HCL): Results of the Acsé Phase II Trial

Xavier Troussard, MD, Laure Montané, Mourad Tiab, Carine Chaleteix, MD, Isabelle Grulois, Clothilde Lindet, Delphine Legoupil, Frederic Kohser, Diane Pannier, Frederic Maloisel, Pierre Bories, Céline AIT Oukhatar, Natalie Hoog Labouret, Jean-Yves Blay, MD PhD

Blood (2017) 130 (Supplement 1): 156.

https://doi.org/10.1182/blood.V130.Suppl_1.156.156

Published: 2017

Journal Articles

Crizotinib in Advanced ALK+ Anaplastic Large Cell Lymphoma in Children and Adults: Results of the Acs© Phase II Trial

Laurence Brugières, Roch Houot, MD PhD, Nathalie Cozic, Christelle De La Fouchardière, Franck Morschhauser, MD PhD, Pauline Brice, MD, Nina Arakelyan Laboure, Anne Auvrignon, Nathalie Aladjidi, MD, Brigitte Kolb, MD, Laurence Blanc, Anne Pagnier, Julia Arfi-Rouche, Anne Ségolène Cottereau, Céline AIT Oukhatar, Natalie Hoog Labouret, Gilles Vassal, MD PhD

Blood (2017) 130 (Supplement 1): 2831.

https://doi.org/10.1182/blood.V130.Suppl_1.2831.2831

Published: 2017

Journal Articles

Outcome of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First Line Therapy: A Swedish Nation-Wide Study on 1053 Consecutive Patients Treated between 2007 and 2013

Sandra Eketorp Sylvan, MD PhD, Anna Asklid, MD, Hemming Johansson, Jenny Klintman, MD PhD, Jenny Bjellvi, MD, Staffan Tolvgård, MD, Eva Kimby, Stefan Norin, MD PhD, P-O Andersson, MD PhD Prof., Claes Karlsson, MD PhD, Karin Karlsson, MD, Birgitta Lauri, MD, Mattias Mattsson, MD, Anna Bergendahl Sandstedt, MD, Maria Strandberg, MD, Anders Österborg, MD PhD Prof., Lotta Hansson

Blood (2017) 130 (Supplement 1): 1744.

https://doi.org/10.1182/blood.V130.Suppl_1.1744.1744

Published: 2017

Journal Articles

Ca 2+ Oscillations and NFATC1 -Activation Enable Oncogenic Signaling in Pre-B Cell Transformation and Leukemogenesis

Kohei Kume, PhD, Liting Chen, PhD, Jaewoong Lee, PhD, Markus Muschen, MD

Blood (2017) 130 (Supplement 1): 2500.

https://doi.org/10.1182/blood.V130.Suppl_1.2500.2500

Published: 2017

Journal Articles

The French LOC Network for Primary CNS Lymphoma (PCNSL) Patients: What Can We Learn from a Large National Database?

Blood (2016) 128 (22): 926.

https://doi.org/10.1182/blood.V128.22.926.926

Published: 2016

Journal Articles

AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo

Erica Hansen, Cyril Quivoron, Kim Straley, René M Lemieux, Janeta Popovici-Muller, Hossein Sadrzadeh, Amir T Fathi, Camelia Gliser, Muriel David, Véronique Saada, Jean-Baptiste Micol, Olivier Bernard, Marion Dorsch, Hua Yang, Michael Su, Sam Agresta, Stéphane de Botton, Virginie Penard-Lacronique, Katharine Yen

Blood (2014) 124 (21): 3734.

https://doi.org/10.1182/blood.V124.21.3734.3734

Published: 2014

Journal Articles

AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

Cyril Quivoron, Muriel David, Kim Straley, Jeremy Travins, Hyeryun Kim, Yue Chen, Dongwei Zhu, Véronique Saada, Olivia Bawa, Paule Opolon, Mélanie Polrot, Jean-Baptiste Micol, Christophe Willekens, Olivier Bernard, Hua Yang, Sam Agresta, Stéphane de Botton, Katharine Yen, Virginie Penard-Lacronique

Blood (2014) 124 (21): 3735.

https://doi.org/10.1182/blood.V124.21.3735.3735

Published: 2014

Journal Articles

Modeling the Epidemiology of Indolent Non-Hodgkin Lymphoma (iNHL) in France

Xavier Troussard, MD PhD, Alain Herrera, MD, Edouard Cornet, Philippe Solal-Céligny, MD

Blood (2014) 124 (21): 5371.

https://doi.org/10.1182/blood.V124.21.5371.5371

Published: 2014

Journal Articles

Modeling the Epidemiology of Chronic Lymphocytic Leukemia (CLL) in France

Xavier Troussard, MD PhD, Alain Herrera, MD, Edouard Cornet, Philippe Solal-Céligny, MD

Blood (2014) 124 (21): 5652.

https://doi.org/10.1182/blood.V124.21.5652.5652

Published: 2014

Journal Articles

International Good Clinical Practices Guidelines (GCPG) for Antithrombotics in CANCER Patients

Blood (2012) 120 (21): 1161.

https://doi.org/10.1182/blood.V120.21.1161.1161

Published: 2012

Journal Articles

Involvement of NFAT Signaling in Function and Anti-Tumor Reactivity of NK Cells

Julia S Wild, Benjamin J Schmiedel, PhD, Melanie Märklin, Lothar Kanz, MD, Martin R Müller, MD, PhD, Helmut R Salih, MD

Blood (2012) 120 (21): 1887.

https://doi.org/10.1182/blood.V120.21.1887.1887

Published: 2012

Journal Articles

International Clinical Practice Guidelines for the Treatment and Prophylaxis of Thrombosis Associated with Central Venous Catheters in Patients with Cancer

Blood (2012) 120 (21): 4357.

https://doi.org/10.1182/blood.V120.21.4357.4357

Published: 2012

Journal Articles

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy

Nina Wagner-Johnston, MD, Andre Goy, MD, Maria Alma Rodriguez, MD, Christopher Ehmann, MD, Paul Hamlin, MD, John Radford, MD, Catherine Thieblemont, MD, Cheolwon Suh, MD, John Sweetenham, MD, Ying Jiang, PhD, Sharon T Sullivan, PhD, Erik R Vandendries, MD, PhD, Christian Gisselbrecht, MD

Blood (2011) 118 (21): 2718.

https://doi.org/10.1182/blood.V118.21.2718.2718

Published: 2011

Journal Articles

An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma,

Michinori Ogura, Toshiki Uchida, David A MacDonald, Kiyohiko Hatake, Andrew Davies, Randeep Sangha, Michael Crump, MD, FRCPC, Catherine Thieblemont, MD, Taro Ishibashi, Steven Hua, Luisa Paccagnella, Erik R Vandendries, MD, PhD, Yukio Kobayashi, Kensei Tobinai, MD

Blood (2011) 118 (21): 3715.

https://doi.org/10.1182/blood.V118.21.3715.3715

Published: 2011

Journal Articles

Analysis of Familial Dysglobulinemia: a Multicenter IFM Study.

Charles Dumontet, Perrine Galia, Xavier Leleu, Herve Avet-Loiseau, Hagay Sobol

Blood (2009) 114 (22): 4891.

https://doi.org/10.1182/blood.V114.22.4891.4891

Published: 2009

NARROW

Implication of Inherited Genetic Variants Associated with Follicular Lymphoma Susceptibility in the Prognosis of Patients Treated By Immunochemotherapy in PRIMA Study

Individualized Prediction of Follicular Lymphoma Risk Using a Combination of Blood t(14;18) Frequency Years before Diagnosis and a Polygenic Risk Score (PRS) of 9 SNPs Associated with Follicular Lymphoma Susceptibility

Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Autonomous Ca 2+ Oscillations Reflect Oncogenic BCR-Signaling in Multiple B-Cell Malignancies and Are Essential for Survival and Proliferation

Vemurafenib in Advanced Patients with Hairy Cell Leukemia (HCL): Results of the Acsé Phase II Trial

Crizotinib in Advanced ALK+ Anaplastic Large Cell Lymphoma in Children and Adults: Results of the Acs© Phase II Trial

Outcome of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First Line Therapy: A Swedish Nation-Wide Study on 1053 Consecutive Patients Treated between 2007 and 2013

Ca 2+ Oscillations and NFATC1 -Activation Enable Oncogenic Signaling in Pre-B Cell Transformation and Leukemogenesis

The French LOC Network for Primary CNS Lymphoma (PCNSL) Patients: What Can We Learn from a Large National Database?

AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo

AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

Modeling the Epidemiology of Indolent Non-Hodgkin Lymphoma (iNHL) in France

Modeling the Epidemiology of Chronic Lymphocytic Leukemia (CLL) in France

International Good Clinical Practices Guidelines (GCPG) for Antithrombotics in CANCER Patients

Involvement of NFAT Signaling in Function and Anti-Tumor Reactivity of NK Cells

International Clinical Practice Guidelines for the Treatment and Prophylaxis of Thrombosis Associated with Central Venous Catheters in Patients with Cancer

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy

An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma,

Analysis of Familial Dysglobulinemia: a Multicenter IFM Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only